Announcement of terms for the fully guaranteed rights issue in OncoZenge, timetable for the listing and record date for Lex Asea
On November 16, 2020, OncoZenge AB (publ), Moberg Pharma's subsidiary, announced that the company had secured financing of a total of approximately SEK 70 million ahead of the spin-off and separate listing on Nasdaq First North Growth Market. Today, the Board of Moberg Pharma has decided that the record date for the right to receive shares in OncoZenge shall be February 5, 2021. The Board of OncoZenge has today, with the support of an authorization from an Extraordinary General Meeting on January 21, 2021, decided on the terms for the rights issue of approximately SEK 60 million (the “Rights